[ad_1]
Today is the 33rd World AIDS Day. These A-share companies are effective against AIDS
Today is the 33rd World AIDS Day. UNAIDS has launched the theme of World AIDS Day 2020: Global solidarity, shared responsibility (prevent and fight AIDS together, share responsibilities for health).
Since the world’s first AIDS case was discovered in 1981, humans have been fighting AIDS for 39 years. Although the fight against “AIDS” has not ceased, in fact AIDS is no longer a terminal disease. There are more than 30 types of AIDS drugs in six categories. In the process of AIDS becoming a chronic disease that can be controlled, companies listed on A shares have not been absent.
Founded in 2013, just made it to the Sci-Tech Innovation BoardFrontier biologyHe is one of the hardest working members. As a leading new AIDS drug company in China, one of the world’s first pharmaceutical companies to focus on developing drugs for patients with long-term syndrome and immunodeficiency virus (HIV). Its flagship product, Aikening, was approved in May 2018. It is listed in China, and for the first time in the Chinese market, long-acting treatment of AIDS has been achieved, with just one drug per week.
The “Aikening + 3BNC117 Combination Therapy” project from the Frontier Bio product portfolio is primarily aimed at the global HIV virus market. It is a new AIDS drug that is focused on the world market. Oral therapy is available and is expected to explore a functional cure for AIDS.
On November 30, Frontier Biotech signed a letter of intent for strategic cooperation with the China Foundation for the Prevention of STDs and AIDS to jointly carry out support activities to improve AIDS prevention and control capabilities and technologies. of China, further promote the construction of grassroots AIDS prevention and control capacities in China and continuously improve the level of treatment, and better To meet the treatment needs of poor patients, jointly carry out prevention and treatment of public welfare.
A few days ago, UNAIDS published the World AIDS Day 2020 report “Focusing on people, we will finally defeat the epidemic”, in which it urged all countries to increase investment, support responses to various diseases and pandemics, and develop a set of bold, ambitious and achievable strategies. The new stage of HIV prevention and control goals. Achieving these goals will help the world get back on track and end the threat of AIDS to public health by 2030.
Among the national pharmaceutical companies committed to “ending the threat of AIDS to public health,” the new star on the science and technology boardAddison PharmaceuticalThe same outstanding performance.
On August 6, Aidi Pharmaceuticals announced that its new class 1 drug ACC007 in the field of AIDS was included in the list of products to be reviewed by the National Center for Drug Evaluation. ACC007 is a non-nucleoside reverse transcriptase inhibitor with a new structure and is the company’s first new class 1 anti-AIDS drug.
Prior to July 29, the ACC008 tablet developed by Aidi Pharmaceuticals for the treatment of treated HIV-1 infected patients was approved for phase III clinical trials. The drug has the characteristics of light medication load, good compliance, and low drug resistance, which will provide domestic patients with a new option that is synchronized with the international one.
Further,Haite BioIt was previously announced that it plans to purchase 67% of the shares of Xiamen Weijia Pharmaceutical Co., Ltd. held by Xinxinyuan for 70.35 million yuan. Weijia Pharmaceutical is focused on the development and production of series of protease inhibitor antiviral products (AIDS drugs) and has mature key technologies for the production of important ritonavir and lopinavir intermediates.
The original third board startups that are impacting the science and technology boardNuotai Bio, Is the manufacturer of advanced pharmaceutical intermediates for American Gilead’s innovative anti-AIDS drug, Biktarvy.
NEEQ companies requesting the selection layerSenxuan Pharmaceutical, It is the largest producer of anti-AIDS intermediates (ritonavir) in China,Pharmaceutical essenceHe directly owns 84.14% of its shares and is the controlling shareholder of the company.
The domestic also includesTohoku Pharmaceutical、Hisun PharmaceuticalThere are generic drugs on the market produced by many pharmaceutical companies for the treatment of AIDS or HIV infection.
As for the AIDS vaccine, although it has not been successfully developed globally so far, many companies are on the way.
DNA-rTV AIDS IIa clinical trials, led by the China Center for Disease Control and Prevention, officially launched at Beijing You’an Hospital and Zhejiang University Medical College First Affiliated Hospital in 2019 The DNA-rTV vaccine is the world’s first replicating virus vector AIDS vaccine that has completed Phase II clinical trials and has received extensive attention and attention from the international AIDS vaccine community.
The “Mosaic” trial sponsored by Janssen Vaccines and Prevention, a subsidiary of Johnson & Johnson Group, has begun phase III clinical trials in the United States, Brazil, and other countries in 2019. Results of the clinical trial are expected to be announced in 2023.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in Charge: Lu Wenyun
